Floatz logo

BMS-986345

Recurrent Nodal Marginal Zone Lymphoma

Narendranath EpperlaPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Recurrent Nodal Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Mayo Clinic
Phase 2B
Zanubrutinib
SWOG Cancer Research Network
Phase 2B
Mosunetuzumab
SWOG Cancer Research Network
Phase 2CCC
Polatuzumab Vedotin
SWOG Cancer Research Network
Phase 2CCC
ETOPOSIDE
University of California, Davis
Phase 2CCC

View all 11 →

Same molecule, other indications

BMS-986345 is also rated in:

Chronic Lymphocytic LeukemiaDormant
B
Indicative ·
58 / 100
View asset →
Follicular LymphomaDormant
B
Indicative ·
56 / 100
View asset →
Indolent Non-Hodgkin LymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →